Literature DB >> 19463689

Coactivator selective regulation of androgen receptor activity.

Irina U Agoulnik1, Nancy L Weigel.   

Abstract

The androgen receptor (AR) is a ligand activated nuclear receptor, which regulates transcription and stimulates growth of androgen dependent prostate cancer. To regulate transcription, AR recruits a series of coactivators that modify chromatin and facilitate transcription. However, information on ligand and target gene-specific requirements for coactivators is limited. We compared the actions of the p160 coactivators SRC-1 and SRC-3/RAC3 with SRA (steroid receptor RNA activator). All three coactivate AR in the presence of agonist as expected. However, overexpression of either SRC-1 or SRC-3 increased AR activity in response to the partial antagonist, cyproterone acetate, whereas SRA was unable to stimulate AR activity under these conditions. Using siRNA to reduce expression of these coactivators in LNCaP cells, we also found promoter specific requirement for these coactivators. SRC-3 is required for optimal androgen dependent induction of PSA, TMPRSS2, and PMEPA1 whereas SRA is required only for optimal induction of the TMPRSS2 gene. These data indicate that different groups of AR target genes have distinct requirements for coactivators and response to AR ligands.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19463689      PMCID: PMC2687407          DOI: 10.1016/j.steroids.2009.02.007

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  22 in total

1.  Repressors of androgen and progesterone receptor action.

Authors:  Irina U Agoulnik; William C Krause; William E Bingman; Hassan T Rahman; Mojghan Amrikachi; Gustavo E Ayala; Nancy L Weigel
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

2.  From estrogen to androgen receptor: a new pathway for sex hormones in prostate.

Authors:  S Yeh; H Miyamoto; H Shima; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

3.  A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA.

Authors:  M Watanabe; J Yanagisawa; H Kitagawa; K Takeyama ; S Ogawa; Y Arao; M Suzawa; Y Kobayashi; T Yano; H Yoshikawa; Y Masuhiro; S Kato
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

4.  Activation of the human androgen receptor through a protein kinase A signaling pathway.

Authors:  L V Nazareth; N L Weigel
Journal:  J Biol Chem       Date:  1996-08-16       Impact factor: 5.157

5.  Steroid receptor RNA activator stimulates proliferation as well as apoptosis in vivo.

Authors:  Rainer B Lanz; Steven S Chua; Niall Barron; Bettina M Söder; Francesco DeMayo; Bert W O'Malley
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

6.  Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase.

Authors:  Irina U Agoulnik; William E Bingman; Manjula Nakka; Wei Li; Qianben Wang; X Shirley Liu; Myles Brown; Nancy L Weigel
Journal:  Mol Endocrinol       Date:  2008-09-11

7.  High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.

Authors:  Rile Li; Thomas Wheeler; Hong Dai; Anna Frolov; Timothy Thompson; Gustavo Ayala
Journal:  Am J Surg Pathol       Date:  2004-07       Impact factor: 6.394

8.  A novel steroid receptor co-activator protein (SRAP) as an alternative form of steroid receptor RNA-activator gene: expression in prostate cancer cells and enhancement of androgen receptor activity.

Authors:  Hidenori Kawashima; Haruna Takano; Syozo Sugita; Yuki Takahara; Kazunobu Sugimura; Tatsuya Nakatani
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  Sequence and characterization of a coactivator for the steroid hormone receptor superfamily.

Authors:  S A Oñate; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Science       Date:  1995-11-24       Impact factor: 47.728

View more
  25 in total

Review 1.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Authors:  Christopher Foley; Nicholas Mitsiades
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

2.  Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells.

Authors:  Manjula Nakka; Irina U Agoulnik; Nancy L Weigel
Journal:  Int J Biochem Cell Biol       Date:  2012-12-25       Impact factor: 5.085

3.  Research resource: expression profiling reveals unexpected targets and functions of the human steroid receptor RNA activator (SRA) gene.

Authors:  Charles E Foulds; Anna Tsimelzon; Weiwen Long; Andrew Le; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  Mol Endocrinol       Date:  2010-03-10

Review 4.  Mechanisms of androgen receptor activation in castration-resistant prostate cancer.

Authors:  Nima Sharifi
Journal:  Endocrinology       Date:  2013-09-03       Impact factor: 4.736

Review 5.  Androgen receptor gene rearrangements: new perspectives on prostate cancer progression.

Authors:  Lucas J Brand; Scott M Dehm
Journal:  Curr Drug Targets       Date:  2013-04       Impact factor: 3.465

Review 6.  Targeting 5α-reductase for prostate cancer prevention and treatment.

Authors:  Lucas P Nacusi; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2011-05-31       Impact factor: 14.432

7.  Influence of ovarian endometrioma on expression of steroid receptor RNA activator, estrogen receptors, vascular endothelial growth factor, and thrombospondin 1 in the surrounding ovarian tissues.

Authors:  Kaiqing Lin; Junyan Ma; Ruijin Wu; Caiyun Zhou; Jun Lin
Journal:  Reprod Sci       Date:  2013-06-07       Impact factor: 3.060

8.  Androgen receptor abnormalities in castration-recurrent prostate cancer.

Authors:  Lucas P Nacusi; Donald J Tindall
Journal:  Expert Rev Endocrinol Metab       Date:  2009-09-01

9.  Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer.

Authors:  Preethi Ravindranathan; Tae-Kyung Lee; Lin Yang; Margaret M Centenera; Lisa Butler; Wayne D Tilley; Jer-Tsong Hsieh; Jung-Mo Ahn; Ganesh V Raj
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.

Authors:  Chuandong Geng; Bin He; Limei Xu; Christopher E Barbieri; Vijay Kumar Eedunuri; Sue Anne Chew; Martin Zimmermann; Richard Bond; John Shou; Chao Li; Mirjam Blattner; David M Lonard; Francesca Demichelis; Cristian Coarfa; Mark A Rubin; Pengbo Zhou; Bert W O'Malley; Nicholas Mitsiades
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.